SD | Jotup

Navigating Challenges and Seizing Opportunities in an Evolving Satellite Landscape

Retrieved on:

星期四, 五月 30, 2024

SINGAPORE, May 30, 2024 - (ACN Newswire) - As the satellite industry continues to evolve, challenges and opportunities abound.

Key Points:

SINGAPORE, May 30, 2024 - (ACN Newswire) - As the satellite industry continues to evolve, challenges and opportunities abound.
Despite challenges, the satellite broadband business remains relevant and lucrative.
The "Asia-Pacific Satellite Leaders Roundtable" also discussed the current state and future outlook of the satellite industry, with a focus on where the video industry is heading.
The Satellite Industry Forum concluded with senior industry executives convening for a high-level discussion on the future trajectory of the satellite industry.

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Retrieved on:

星期五, 五月 31, 2024

Brenetafusp was shown to be well tolerated, in monotherapy and in combination with anti-PD1, and demonstrated durable clinical benefit.

Key Points:

Brenetafusp was shown to be well tolerated, in monotherapy and in combination with anti-PD1, and demonstrated durable clinical benefit.
“We expect brenetafusp PFS to be even higher in first-line based on our analysis of blood T cell fitness.
All monotherapy treated patients had received prior immune checkpoint inhibitors (100% anti-PD1, 81% anti-CTLA4).
Immunocore will host a conference call today, May 31, 2024 at 7:15 PM ET / 6:15 PM CT, to discuss the Phase 1 PRAME expansion data and Phase 3 registrational trial in cutaneous melanoma.

CloudFabrix to demonstrate its Unified Network Observability and Automation solution, now also available on Splunk, at CiscoLive 24

Retrieved on:

星期五, 五月 31, 2024

Technology, Networks, Robotics, Data Management, Cloud, LLDP, VMware, Ecosystem, OSPF, SDWAN, RAG, LLM, RDA, Meraki, Infrastructure, Macaw, Multimedia, Radar, BGP, Intelligence, CLI, Security, Multi, Telemetry, ThousandEyes, Platform, RDAF, PRTG, SNMP, GRPC, Data, API, Network, Challenger, AI, Service, IBM Consulting, EMA, Root cause analysis, CDP, Financial services, Performance management, Mobile phone

The stakes for an unified network observability and automation solution have never been higher, which becomes the central single pane of Ops across observability, security and networking siloed domains.

Key Points:

The stakes for an unified network observability and automation solution have never been higher, which becomes the central single pane of Ops across observability, security and networking siloed domains.
CloudFabrix’s Unified Network Observability and Automation solution specifically addresses these challenges.
“Our clients will benefit from the CloudFabrix Unified Network Observability and Automation solution.
Much of the CloudFabrix Unified Network Observability offering is built on its Robotic Data Automation Fabric (RDAF), which creates rich pipelines anywhere in the infrastructure.” said Ron Williams, Principal analyst Gigaom.

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

Retrieved on:

星期四, 五月 30, 2024

XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection of levothyroxine.

Key Points:

XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection of levothyroxine.
The Phase 2 study included the following periods: Screening, Titration Period (2 to 8 weeks), and Maintenance Period (4 weeks).
Participants entered the study on a stable oral dose (≥ 3 months) with normal TSH and free T4 laboratory values.
Participants were receiving a daily oral levothyroxine dose of 83.7 ± 31.14 mcg (mean ± SD) at study entry.

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Retrieved on:

星期二, 五月 28, 2024

DOYLESTOWN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that the Safety Review Committee (SRC) overseeing the ongoing ABOYA-119 clinical trial has determined that dosing of patients with ATRN-119 at 800 mg once daily (Cohort 6) can commence and that Cohort 6 is open for enrollment. This decision follows review of the safety and pharmacokinetic data from patients treated at 550 mg once daily (Cohort 5).

Key Points:

This decision follows review of the safety and pharmacokinetic data from patients treated at 550 mg once daily (Cohort 5).
“Pharmacokinetic data show that the duration of systemic exposure substantially increases with each dose level of ATRN-119.
A total of 17 patients have been enrolled in the first five cohorts of the dose escalation stage (50 mg once daily, 100 mg once daily, 200 mg once daily, 350 mg once daily, and 550 mg once daily).
The data demonstrate near dose proportional exposure following oral administration of ATRN-119 doses between 50 mg once daily to 550 mg once daily.

EFI Presents Revolutionary Innovations for Packaging, Display Graphics, and Textiles at drupa 2024

Retrieved on:

星期二, 五月 28, 2024

MP, Running, Economics, Automation, TCO, XP, LED, Electronics, Printing, Reggiani, EFI, Acquisition, Nozomi, Exhibition, GM, RSVP, Software, Textile, Lunch, Ordinance, Water, 3D printing

today unveiled a wide array of innovative solutions in inkjet printing for packaging, display graphics, and textiles, all on display at its stand at drupa 2024, opening today and running through 7 June at Messe Düsseldorf.

Key Points:

today unveiled a wide array of innovative solutions in inkjet printing for packaging, display graphics, and textiles, all on display at its stand at drupa 2024, opening today and running through 7 June at Messe Düsseldorf.
“Our return to drupa brings some of the most transformative announcements in EFI history,” said Frank Pennisi, CEO of EFI.
Featured live at EFI’s stand is the must-see Packsize® EFI™ X5® Nozomi, the world's first full-colour, on-demand, right-sized box system.
In other packaging news, EFI announced the EFI Nozomi 14000 AQ true water-based, single-pass inkjet technology for corrugated packaging and displays.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

Retrieved on:

星期二, 五月 28, 2024

HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

Key Points:

HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
Abstract (5562) demonstrates promising safety and efficacy data of TILT-123 in ovarian cancer patients, whilst abstract (2658) demonstrates the potential for TILT-123 as an intravenous therapy.
14 patients (out of 15 enrolled) were evaluable for treatment response, with disease control achieved in 64.3%.
This means TILT-123 reached tumors, despite not being directly injected into them, and successfully triggered an immune system toward the cancer.

Investor heterogeneity and large-scale asset purchases

Retrieved on:

星期二, 五月 28, 2024

OLS, Regression analysis, Friedman, Journal of Financial Economics, PSPP, Investment management, P50, Classification, Research Papers in Economics, Social science, Institution, Federal Reserve, Public sector, Harvard University, Central bank, Bartik, 2SLS, Total, Bank of Italy, Quarterly Journal, Medical classification, Elsevier, JEL, FE, SHS, Əbil, HBS, Language, ECB, Credit, Regulation, APP, Reproduction, Lipper, CSDB, International Monetary Fund, CUSIP, Observation, Database, RX2, G11, SUTVA, P90, Financial economics, Table, Ben Bernanke, Financial intermediary, American Economic Review, Pension, Gundibail Sunderam, Paper, European Central Bank, Great, Imperial College London, Employment, Calibration, Literature, Intuition, QE, EMU, SSRN, G23, Appendix, Research, Fed, Treasury, Share, Fahd of Saudi Arabia, Quantity, Policy, International, BIS, PDF, Technical report, Insurance, B.1, Website, Political economy, Data, PEPP, G12, Bank of England, University, Exercise, Weight function, Quantitative easing, Government, UIUC, Quarterly Journal of Economics, Bank, P10, R2, DeSantis, E58, Security (finance)

We quantify both the direct and the portfolio re-balancing impact,

Key Points:

We quantify both the direct and the portfolio re-balancing impact,
emphasizing the role of investor heterogeneity.
By purchasing large quantities of assets, the central banks aim to affect asset prices
throughout the economy.
In this paper, we set out to deal with these challenges and to quantify both the direct
and indirect effects of large-scale asset purchases.
In this paper, we set out to deal with these challenges and to quantify both the direct
and indirect effects of large-scale asset purchases.
In the first part of the paper, we assess the importance of investor heterogeneity for
the direct effects of central bank purchases.
Large-scale asset purchases are isomorphic to
negative changes in supply, as they effectively reduce the supply of bonds available to private
investors in the market.
We weigh the estimates by the portfolio composition (number of
securities held) of the respective asset types for the average fund.
ECB Working Paper Series No 2938
5

price of one security depends on the slope of the demand curve for that asset.
However, in our setting, supply changes are not
necessarily randomly allocated, as purchases could be correlated with asset characteristics.
To address this challenge, we isolate a random component of purchases and, with that,
estimate the price elasticity of each type of investor.
For each investor type, we regress
the security holdings on that security?s yield, instrumenting the yield with ECB purchases.
Given the estimated investor elasticities, we construct a security-level measure of the
price elasticity of the investor base.
To address this concern, we exploit quasi-exogenous cross-sectional variation in
investor base composition across securities, measuring the share held by each investor type
prior to the announcement and implementation of asset purchases.
With this measure, we can finally test how investor composition affects the direct impact of
central bank purchases.
In
this part of the analysis, we focus on mutual funds, one investor type we estimated to be
elastic.
This insight can help assess the calibration and targeting of asset purchase programs by central banks based on their objective
function.
This paper relates to several strands of literature on unconventional monetary policy, intermediary and demand-system asset pricing.
First, we relate to the literature on large-scale asset purchases in the Euro Area, studying announcement effects of purchases (Andrade et al.
We contribute to
this literature by estimating spillover effects on assets that are not eligible for central bank
purchases while emphasizing the role of investor heterogeneity and developing a novel identification methodology.
Our contribution to this literature is to analyze the role of investors?
preferences for the propagation of large scale asset purchases.
Then the aggregate demand curve for the asset is
X
k
?k x k =

X

?k (?k ? p?k )

k

where ?k is the share of investor k in the market.
P
By adding market clearing (S = k ?k xk ) we can derive that the price of the asset takes
the following form:
P
?k ?k
S
p = Pk
?P
.
We denote with Dt = [dt,k , dt,k? , ...dt,K ] the N xK matrix of
demand of each investor type for each security.
4
Direct effects and investor heterogeneity

In this section we study the following research question: do effects of asset purchases depend
on investor composition?
In order to answer this question, we test how purchases affect yields and how these effects
vary as investor composition changes.
Third, we measure investor composition by exploiting
quasi-random variation in ex-ante investor composition.
In the next section we will investigate how this
security-level heterogeneity in investor composition matters for the effects of asset purchases.
4.2
Demand elasticities of investors

In this section we investigate how different investor types react to Large Scale Asset Purchases
(LSAPs).
In section 4 we estimated heterogeneity in elasticity across investor types based on how
price-elastic they were to ECB purchases.
These results are in line with Table 3,
where we estimate heterogeneity in elasticity across investor types.
To measure investor composition base heterogeneity we construct
ECB Working Paper Series No 2938

38

security-level Weighted elasticity as we did in section 4.
Weighted Elasticity: Bn,t?1 =
X

??n,k,t?1 ?k

(8)

k

where ??n,k,t?1 is the share of the asset n held by investor k at t-1 and ?k are the elasticities
of investor types estimated in section 4.
7
Conclusion

In this paper, we examine the role of investor heterogeneity for both direct and indirect
effects of central bank purchases.
Our findings show substantial heterogeneity in
exposure to large-scale asset purchases across mutual funds.

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors

Retrieved on:

星期四, 五月 23, 2024

The poster presentation, which constitutes the first report of long-term efficacy, safety, and pharmacokinetic (PK) data from the Phase 1 study, also suggests that sudocetaxel zendusortide has a manageable safety profile when dosed at 300mg/m2, with few Grade 3 adverse events (AEs).

Key Points:

The poster presentation, which constitutes the first report of long-term efficacy, safety, and pharmacokinetic (PK) data from the Phase 1 study, also suggests that sudocetaxel zendusortide has a manageable safety profile when dosed at 300mg/m2, with few Grade 3 adverse events (AEs).
“It is highly unusual to see such long-lasting disease stabilization even after treatment cessation in patients with advanced disease.
Sudocetaxel zendusortide has a manageable safety profile, with most treatment-related AEs rated as mild to moderate in severity and managed with standard supportive care or dose reductions.
The maximum concentration (Cmax) of sudocetaxel zendusortide was 30.4 micromolar (μM), compared to 0.58 μM for free docetaxel.

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

Retrieved on:

星期四, 五月 23, 2024

Ragistomig was designed as a bispecific antibody to provide anti-PD-L1 activity and 4-1BB-driven T-cell activation in one molecule.

Key Points:

Ragistomig was designed as a bispecific antibody to provide anti-PD-L1 activity and 4-1BB-driven T-cell activation in one molecule.
“We are pleased to present the Phase 1 data to date for ragistomig at ASCO 2024.
These data support further development of ragistomig as both a monotherapy and in combination with other compounds.
Observation of responses is also encouraging, including a 25% ORR and a 75% clinical benefit rate (CBR), at the optimal dose of 5 mg/kg.